Home 2024

Archives

Novel conjugate vaccines are generated by attaching various immune agonists to Chlamydia antigens using cell-free protein synthesis and click-chemistry. These vaccines are then tested in pre- clinical animal models for immunogenicity and efficacy. The top candidate(s) will progress to phase 1 clinical trials to determine safety and effectiveness against genital and ocular Chlamydia infections.

Advancing vaccine development for chlamydia

Genital Chlamydia trachomatis infection is a significant public health burden; Professor of Pediatrics and Microbiology and Immunology, Toni Darville, discusses the potential efficacy of CPAF-adjuvanted vaccines in mitigating the spread and impact of the infection.

Follow Us

Advertisements

Open Access Government

Open Access Government produces compelling and informative news, publications, eBooks, and academic research articles for the public and private sector looking at health, diseases & conditions, workplace, research & innovation, digital transformation, government policy, environment, agriculture, energy, transport and more.

Follow Us

Resources

Quick Links

Legal & Marketing

As a Crossref Sponsored Member we are able to connect your content with a global network of online scholarly research, currently over 20,000 other organizational members from 160 countries. Crossref drive metadata exchange and support nearly 2 billion monthly API queries, facilitating global research communication.

© Adjacent Digital Politics Ltd